InnoCare Pharma Limited (SHA:688428)

China flag China · Delayed Price · Currency is CNY
23.30
+0.15 (0.65%)
At close: Feb 27, 2026
Market Cap21.35B +105.3%
Revenue (ttm)1.43B +58.7%
Net Income-229.64M
EPS-0.14
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,740,219
Average Volume11,673,693
Open23.10
Previous Close23.15
Day's Range23.03 - 23.45
52-Week Range15.18 - 34.02
Beta0.59
RSI53.80
Earnings DateMar 26, 2026

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 1,176
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688428
Full Company Profile

Financial Performance

In 2024, InnoCare Pharma's revenue was 1.01 billion, an increase of 36.68% compared to the previous year's 738.54 million. Losses were -440.63 million, -30.20% less than in 2023.

Financial Statements